



# Epidemiology of Plasmid Lineages Mediating the Spread of Extended-Spectrum Beta-Lactamases among Clinical *Escherichia coli*

Bejan Mahmud,<sup>a</sup> Meghan A. Wallace,<sup>b</sup> Kimberly A. Reske,<sup>c</sup> Kelly Alvarado,<sup>b</sup> Carol E. Muenks,<sup>b</sup> David A. Rasmussen,<sup>d,e</sup> Carey-Ann D. Burnham,<sup>b,c,f,g</sup> Cristina Lanzas,<sup>h</sup> Erik R. Dubberke,<sup>c</sup> Gautam Dantas<sup>a,b,f,i</sup>

<sup>a</sup>The Edison Family Center for Genome Sciences & Systems Biology, Washington University School of Medicine, St. Louis, Missouri, USA

<sup>b</sup>Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA

<sup>c</sup>Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA

<sup>d</sup>Department of Entomology and Plant Pathology, North Carolina State University, Raleigh, North Carolina, USA

<sup>e</sup>Bioinformatics Research Center, North Carolina State University, Raleigh, North Carolina, USA

<sup>f</sup>Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA

<sup>g</sup>Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA

<sup>h</sup>Department of Population Health and Pathobiology, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA

<sup>i</sup>Department of Biomedical Engineering, Washington University in St. Louis, St. Louis, Missouri, USA

**ABSTRACT** The prevalence of extended-spectrum beta-lactamases (ESBLs) among clinical isolates of *Escherichia coli* has been increasing, with this spread driven by ESBL-encoding plasmids. However, the epidemiology of ESBL-disseminating plasmids remains understudied, obscuring the roles of individual plasmid lineages in ESBL spread. To address this, we performed an in-depth genomic investigation of 149 clinical ESBL-like *E. coli* isolates from a tertiary care hospital. We obtained high-quality assemblies for 446 plasmids, revealing an extensive map of plasmid sharing that crosses time, space, and bacterial sequence type boundaries. Through a sequence-based network, we identified specific plasmid lineages that are responsible for the dissemination of major ESBLs. Notably, we demonstrate that IncF plasmids separate into 2 distinct lineages that are enriched for different ESBLs and occupy distinct host ranges. Our work provides a detailed picture of plasmid-mediated spread of ESBLs, demonstrating the extensive sequence diversity within identified lineages, while highlighting the genetic elements that underlie the persistence of these plasmids within the clinical *E. coli* population.

**IMPORTANCE** The increasing incidence of nosocomial infections with extended-spectrum beta-lactamase (ESBL)-producing *Escherichia coli* represents a significant threat to public health, given the limited treatment options available for such infections. The rapid ESBL spread is suggested to be driven by localization of the resistance genes on conjugative plasmids. Here, we identify the contributions of different plasmid lineages in the nosocomial spread of ESBLs. We provide further support for plasmid-mediated spread of ESBLs but demonstrate that some ESBL genes rely on dissemination through plasmids more than the others. We identify key plasmid lineages that are enriched in major ESBL genes and highlight the encoded genetic elements that facilitate the transmission and stable maintenance of these plasmid groups within the clinical *E. coli* population. Overall, our work provides valuable insight into the dissemination of ESBLs through plasmids, furthering our understating of factors underlying the increased prevalence of these genes in nosocomial settings.

**KEYWORDS** *Escherichia coli*, beta-lactamases, plasmid-mediated resistance

**Editor** Christopher W. Marshall, Marquette University

**Copyright** © 2022 Mahmud et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Cristina Lanzas, [clanzas@ncsu.edu](mailto:clanzas@ncsu.edu), Erik R. Dubberke, [edubberk@wustl.edu](mailto:edubberk@wustl.edu), or Gautam Dantas, [dantas@wustl.edu](mailto:dantas@wustl.edu).

The authors declare no conflict of interest.

[This article was published on 22 August 2022 with errors in Fig. S3. The figure was corrected in the revised version, posted on 7 September 2022.]

**Received** 3 June 2022

**Accepted** 2 August 2022

**Published** 22 August 2022


Since their first report in the 1980s, extended-spectrum beta-lactamase (ESBL)-producing *Enterobacteriales* have spread globally; it is now estimated that approximately 1.5 billion people are colonized with such organisms (1). Infections with ESBL-producing *Enterobacteriales* are associated with a higher likelihood of treatment failure, higher mortality, and added financial burdens on the patients and the healthcare system (2). While historically the TEM and SHV ESBL families were the predominant genes found in infectious isolates, the CTX-M group of ESBLs has emerged more recently as the most prevalent and has driven the global ESBL dissemination (3, 4). *Escherichia coli* is the primary carrier of the CTX-M family of ESBLs (3), and the rates of community carriage of ESBL-producing *E. coli* are on the rise, particularly in low- and middle-income countries (5). The spread of ESBL *E. coli* in nosocomial settings is even more pervasive: the rates of ESBL production among clinical *E. coli* isolates have steadily increased globally over the years, with the reported ESBL rates among hospital-associated infections in the US being as high as 27.7% (4, 6, 7).

The widespread dissemination of the CTX-M gene family in health care settings is attributed to the association of these genes with mobile genetic elements (MGEs) (5) in this environment with high antibiotic selective pressure. Of particular interest are the conjugative IncF family of plasmids, which have been reported as one of the primary culprits for the spread of ESBLs (8–11). Consequently, various plasmid curing mechanisms, such as conjugation inhibitors, have been proposed to be used clinically to ease the ESBL resistance burden (12, 13). However, the potential benefits of such proposals remain partially obscured by the understudied epidemiology of ESBL-encoding plasmids. Specifically, while numerous studies have successfully described plasmids carrying ESBLs, such efforts have typically focused on epidemiologically unrelated plasmids (14–19), had a relatively small plasmid set (14, 20–24), or were methodologically limited in their resolution (15–18, 21, 25–28). As such, questions remain regarding the dynamics of plasmids mediating the spread of ESBLs within defined health care systems. Specifically, the extent of plasmid sharing within a clinical *E. coli* population, the roles of different plasmid lineages in the local spread of individual ESBLs, and the long-term genetic stabilities of such lineages remain underexplored.


To address the above knowledge gaps, we conducted an in-depth, high-resolution, genomic analysis of 149 clinical ESBL *E. coli* isolates collected over a 3-year period from a single tertiary-care hospital. We identified an extensive network of plasmid sharing that crosses time, space, and phylogenetic barriers. IncF plasmids were found to be significantly enriched in ESBL genes, constituting 2 distinct plasmid lineages that are associated with different ESBL genes and occupy varying host ranges. However, plasmid-mediated resistance spread was not uniform, as certain ESBLs were predominantly chromosomally encoded and may thus rely more on bacterial host clonal expansion for their dissemination.

## RESULTS

**Sample description.** A total of 367 blood or urine specimens that grew ESBL *E. coli* were collected during the study period from patients admitted to the medical and/or oncology wards and intensive care units of the Barnes-Jewish Hospital between June 2016 and December 2019. After excluding duplicate specimens collected within 14 days of an initial specimen, 313 specimens were eligible for inclusion (see Materials and Methods). Of these, remnant specimens were available for 149 *E. coli* isolates (47.6% of the total eligible specimens), originating from a cohort of 129 patients; most of the patients contributed only a single isolate (see Materials and Methods) (Table S1). All isolates displayed phenotypic susceptibility patterns characteristic of ESBL-producing strains, namely, resistant to at least one third generation cephalosporin and susceptible to cephamycins (see Materials and Methods). Phylogenetic clustering of isolates by specimen type (urine versus blood) and collection ward (medical versus oncology) was not observed (Fig. 1a). Multi-locus sequence typing using the Achtman scheme (29) identified 27 distinct sequence types



**FIG 1** Abundance of *E. coli* sequence types (STs) and extended-spectrum beta-lactamases (ESBLs). (a) Maximum likelihood phylogenetic tree from the alignment of 2,888 core genes of the 149 ESBL *E. coli* isolates. The outer rings are colored to indicate the major STs, collection wards, and the types of originating clinical specimens. Sequence typing of the isolates was done using the Achtman scheme. (b) Abundances of ESBL genes and major STs are shown as bar plots. The identified ST-ESBL pairs are shown in circles, and the sizes of the circles are proportional to the number of instances of the given pair identified in our isolate set; the ST-ESBL pair counts are indicated in the circles. The isolates containing multiple copies of the same gene were counted only once toward the corresponding ST-ESBL pair.




**FIG 2** Persistence of a *bla*<sub>CTX-M-14</sub>-encoding *E. coli* lineage. The left panel displays a phylogenetic tree of the 8 isolates identified to be highly related. Relatedness is determined through the number of single-nucleotide polymorphisms (SNPs) across 4,925,981 chromosomal core sites, defined as sites present in all isolates. The branch lengths indicate the SNP distances among isolates. All pairs of isolates are within 174 SNPs of each other. The right panel shows the collection dates (x axis) for the 8 isolates, denoted by red circles. The size of the circles corresponds to the number of *bla*<sub>CTX-M-14</sub> gene copies found within the given isolate. Isolates 144, 145, and 146 were isolated from the same patient; other isolates originated from distinct patients.

(STs) (Fig. S1). Consistent with the previous reports of its global prevalence (30, 31), ST131 was most frequently recovered from our patient cohort (Fig. 1b and Fig. S1).

**Variability in genetic origins of ESBLs.** Overall, we identified 8 distinct ESBL genotypes in our isolates (Fig. 1b). Among identified ESBLs, *bla*<sub>CTX-M-15</sub> was the most common (Fig. 1b and Fig. S1). Similarly, the *bla*<sub>CTX-M-15</sub>-ST131 pairing was most common in our data set; however, significant enrichment of the gene in ST131 hosts was not observed ( $P = 0.36$ , Chi-Square goodness of fit, Bonferroni correction for multiple comparisons). Instances of isolates carrying 2 distinct ESBL genes were uncommon but present, with 2 isolates encoding both *bla*<sub>CTX-M-15</sub> and *bla*<sub>CTX-M-14</sub>, another isolate encoding for *bla*<sub>CTX-M-27</sub> and *bla*<sub>CTX-M-55</sub>, and the pair of *bla*<sub>CTX-M-15</sub> and *bla*<sub>CTX-M</sub> found in yet another isolate (Data Set S1, Sheet A). Despite displaying an ESBL-like phenotype (see Materials and Methods), no known ESBL genes were identified in 8 of the isolates (Data Set S1, Sheet A).

The genetic origin (chromosomal versus plasmidic) of resistance genes is a major determinant of transmission routes (vertical versus horizontal) and has been noted to affect antibiotic susceptibility in the bacterial host (32). Accordingly, we investigated the distribution of ESBLs between chromosomal and plasmidic contigs in our cohort (Table S2). The genetic origins of the major ESBL genotypes varied considerably. *bla*<sub>CTX-M-14</sub> was spread evenly between the 2 genetic elements. *bla*<sub>CTX-M-15</sub> was predominantly encoded chromosomally, whereas *bla*<sub>CTX-M-27</sub> and *bla*<sub>CTX-M-55</sub> were predominantly found in plasmids (Table S2).

**Amplification of *bla*<sub>CTX-M-14</sub> within a persistent *E. coli* lineage.** Several isolates in our set carried multiple copies of a given ESBL gene. The presence and biological significance of multiple ESBL gene copies in *E. coli* isolates have been noted before (33–35). Specifically, isolates with multiple copies of *bla*<sub>CTX-M-15</sub>, *bla*<sub>CTX-M-14</sub>, *bla*<sub>CTX-M-27</sub>, or *bla*<sub>CTX-M-55</sub> were identified in our set (Data Set S1, Sheet A). Most notably, isolate 146 was found to carry 4 copies of *bla*<sub>CTX-M-14</sub>, 3 encoded in distinct and distant chromosomal loci and 1 copy carried in a plasmid (Fig. 2 and Fig. S2b). Interestingly, isolate 146 was the latest of the 3 isolates (144–146) cultured across a year-long period from urine samples of the same patient. These isolates likely constitute a single lineage, and all carry a 75-Kb plasmid encoding *bla*<sub>CTX-M-14</sub> (Fig. 2 and Fig. S2a). However, the isolates differ in the number of chromosomal copies of *bla*<sub>CTX-M-14</sub>, with 2 copies in 145 and none in 144, suggesting that this lineage has experienced an enrichment in the *bla*<sub>CTX-M-14</sub> copy number over the course of the disease. Furthermore, isolates from the same lineage were also identified in urine samples collected over a 2-year period from other patients




**FIG 3** Transposases associated with major extended-spectrum beta-lactamases (ESBLs). Conserved genetic cassettes encoding *bla*<sub>CTX-M-14</sub> (a), *bla*<sub>CTX-M-55</sub> (b), *bla*<sub>CTX-M-15</sub> (c,d), and *bla*<sub>CTX-M-27</sub> (e,f). BLASTn similarity scores of 100% (rounded to the nearest integer) colored in accordance with the matching orientation (i.e., forward or reverse). Protein annotations are shown in arrows. ESBLs and relevant nearby open reading frames are colored. Truncated open reading frames are indicated with  $\Delta$ . The chromosomal (C) or plasmidic (P) origins of the genetic elements are indicated.

(Fig. 2), and all similarly carry the aforementioned *bla*<sub>CTX-M-14</sub>-encoding 75-Kb plasmid (Fig. S2a). Chromosomal copies of *bla*<sub>CTX-M-14</sub> were also identified in 2 other isolates (Fig. 2), suggesting that resistance gene amplification is not limited to the patient harboring isolates 144–146 and is a more general feature of this lineage. These data demonstrate the clinical persistence of an infectious *E. coli* lineage, and dissemination and amplification of an ESBL through association with this lineage.

**ESBLs are commonly encoded within conserved transposable elements.** ESBL genes were often encoded near transposases within conserved cassettes. Analysis of the *bla*<sub>CTX-M-14</sub> genomic context within chromosomal and plasmidic copies of the gene found in isolates 144, 145, and 146 identified the gene within a conserved cassette encoding the *ISEcp1* transposase upstream of the gene in all instances (Fig. S2b). Such genetic organization was observed in other, distantly related isolates carrying *bla*<sub>CTX-M-14</sub> (Fig. 3a), with the gene located downstream of *ISEcp1* in 92.3% (36/39) of the instances in our data set. Similarly, *bla*<sub>CTX-M-55</sub> was most commonly (56.4%, 11/18) observed to be encoded within a conserved cassette downstream of the *ISEcp1* (Fig. 3b); *bla*<sub>CTX-M-55</sub> was often (33.3%, 6/18) found downstream of *IS15* as well. *ISEcp1* was also associated with *bla*<sub>CTX-M-15</sub>, which was typically (65.4%, 53/81) found to be located within a conserved unit downstream of the transposase (Fig. 3c). This *ISEcp1*-*bla*<sub>CTX-M-15</sub> configuration is seldom found within a larger conserved window that also encodes for the *TEM-1* broad-spectrum beta-lactamase and the *Tn3* resolvase (36). Such prevalent association of *ISEcp1* with 3 of the 4 most common ESBL genotypes suggests that the transposase is predominantly responsible for the dissemination of ESBLs within our clinical population.

Another notable transposase associated with *bla*<sub>CTX-M-15</sub> is *IS26*, which was commonly (29.6%, 24/81) found upstream of the resistance gene (35) (Fig. 3d). *IS26* may also drive the mobilization of *bla*<sub>CTX-M-27</sub> within our clinical isolates, as the transposase was identified upstream of *bla*<sub>CTX-M-27</sub> in 83.9% (26/31) of instances, commonly encoding *IS903* (35.5%, 11/31) (Fig. 3e) or *IS15* (38.7%, 12/31) (Fig. 3f) downstream of the resistance gene. The latter conformation, *IS26*-*bla*<sub>CTX-M-27</sub>-*IS15*, was located within a conserved  $\sim$ 20-Kb window (37). An *IS26*-flanked sub-region within this window was found inverted in 1 of our plasmids, suggesting its capacity for mobilization independent of the 20-Kb segment (Fig. 3f). All major ESBL genotypes found in our set are commonly encoded within conserved windows proximal to transposases (primarily *ISEcp1* and *IS26*), which have likely contributed to






**FIG 4** Plasmids carried by extended-spectrum beta-lactamase (ESBL)-encoding *E. coli* isolates. (a) Histogram depicting the distribution of assembled plasmidic contigs by size. The fractions of plasmids encoding ESBLs, non-ESBL antimicrobial (AMR) genes, and lacking AMR genes in each bin are colored. Bin size = 10 Kb. (b) Maximum likelihood phylogenetic tree of the 149 ESBL *E. coli* isolates. Isolates are colored by major sequence types (STs). The inner lines connect isolate pairs with >550 single-nucleotide polymorphisms (2,888 core genes; Fig. S3), in which near-identical pair of plasmids (i.e., shared plasmids) were identified. Two plasmids were defined to be near-identical if they i) had  $\geq 95\%$  coverage and  $\geq 99\%$  identity by BLASTn, and ii) did not differ in size by more than 10% of the larger of the two plasmids. The connecting lines are colored to indicate sharing of non-ESBL plasmids within and across ST, and sharing of ESBL-encoding plasmids within ST. Thickness of the lines corresponds to the average of the sizes of the two plasmids.

within-isolate gene multiplication events and facilitated the within-population spread of the resistance genes (i.e., through transposition to a plasmid).

**Sharing of plasmids across space, time, and genetic barriers.** Plasmids are the predominant units of horizontal transmission of ESBLs and are likely responsible for their rapid global spread (38). We conducted an in-depth analysis of the total plasmid content of our isolate set to identify genetic patterns associated with the spread of ESBLs. Contigs were labeled as plasmidic if they were: i) under 1M-bp in length and ii) circular. We identified 446 plasmidic contigs, with the mode of 2 plasmids/isolate and a range of 1–10 plasmids/isolate. The identified plasmid sizes ranged from 1,547 bp to 320,261 bp and displayed a multimodal distribution, with a large number of plasmids under 20 Kb in size and mostly devoid of antimicrobial resistance genes (Fig. 4a).

We identified numerous instances of plasmid sharing between distantly related isolates (>550 core single-nucleotide polymorphisms [SNPs]) (Fig. S3). Plasmids were compared via BLASTn in all pairwise combinations, and the hits with  $\geq 95\%$  coverage,  $\geq 99\%$  identity, and not differing in size by more than 10% of the larger of the 2 plasmids in the pair were considered as potential instances of plasmid sharing. Furthermore, to account for acquisition/loss of transposable fragments by plasmids (Fig. S4a) and to minimize the rate of false matches, we only considered plasmid pairs where the corresponding sizes did not differ by more than 10% of the larger value. We identified an extensive network of plasmid sharing within our sample set (Fig. 4b). Sharing of plasmids across STs is common, with 31 unique ST pairs identified in this network. Near-identical plasmids were found in isolates collected as long as 3 years apart from distinct patients (mean of 383 days between collections); moreover, a quarter of such plasmids were present in isolates from both medical and oncology wards. We also observed sharing of ESBL-encoding plasmids by phylogenetically distant isolates (Fig. 4b). Notably, near-identical *bla*<sub>CTX-M-55</sub>-encoding plasmids were present in urine isolates (103 and 138) collected a year apart from distinct patients (Fig. S4a). Numerous instances of phylogenetically distant isolates carrying multiple near-identical plasmids were also identified. Most notably, blood isolates 113 and 114, collected 2 months apart from the same patient, both carried a *bla*<sub>CTX-M-55</sub>-encoding 48-Kb and a



**FIG 5** Clustering of plasmids by average-nucleotide identity (ANI). Similarity network of the 446 plasmids assembled from hybrid sequencing of the 149 ESBL *E. coli* isolates. Plasmids are represented by nodes. Pairs of nodes are connected with edges with weights corresponding to the ANI scores. The network is colored by identified modules (a), major replicon types (b), and major sequence types (STs) of the corresponding hosts (c).

103-Kb plasmids (Fig. S4b and c). Our network analysis of shared plasmids demonstrates the persistence of plasmids across space and time within a diverse set of clinical hosts, and commonplace plasmid sharing unrestricted by ST boundaries.

**ESBLs are disseminated through distinct plasmid groups.** The plastic genetic architecture of plasmids impedes efficient tracking of plasmid families responsible for dissemination of resistance genes based on high BLAST coverage and identity matches alone (39) (Fig. S4d). To address that, we implemented an average-nucleotide identity (ANI)-based clustering method that reveals groups of functionally related plasmids (40). Briefly, ANI scores were calculated for all pairwise combinations of the 446 plasmids. ANI values were filtered by coverage and transformed into edge weights to be used in a network with each plasmid represented by a node. After network spatialization, the clusters were identified via modularity optimization (see Materials and Methods). We identified 15 groups (hereafter referred to as modules) of related plasmids (Fig. 5a). The identified modules separate well by replicon types (Fig. 5b) and mobilization families (Fig. S5b), and primarily consisted of similarly-sized plasmids (Fig. S5a).

Specific plasmid modules are significantly associated with different ESBL genes, presenting such modules as primary agents of horizontal spread of ESBLs. Module 6 was identified to be significantly enriched in *bla*<sub>CTX-M-15</sub> ( $P = 0.009$ , Chi-Square goodness of fit) (Fig. S5c). Module 6 comprises 36 plasmids belonging predominantly to the IncI group (Fig. 5b) and encoding the MOB family of relaxases (Fig. S5b). Plasmids within module 6 were found in isolates representing 13 distinct sequence types (Fig. 5c), with only 36% (13/26) associated with ST131, suggesting a broader host range of this plasmid group relative to other modules. As before, *bla*<sub>CTX-M-15</sub> genes within this module were predominantly (71.4%, 5/7) encoded downstream of *ISEcp1*. Module 11 plasmids, on the other hand, were found to be significantly enriched in *bla*<sub>CTX-M-14</sub> ( $P = 4.8 \times 10^{-4}$ , Chi-Square goodness of fit); this module consists of 8 IncB plasmids with MOB family of relaxases, primarily hosted by ST131 (4/8, 50%) and ST648 (3/8, 37.5%) *E. coli* isolates.

IncF family of plasmids have been hypothesized to be the primary carriers of ESBLs, particularly of *bla*<sub>CTX-M-15</sub> (8–11). Both antibiotic resistance genes ( $P = 0.0104$ , Chi-Square goodness of fit) and ESBLs ( $P = 2.35 \times 10^{-19}$ , Chi-Square goodness of fit) were enriched in IncF plasmids relative to other plasmid types (Fig. S5c and d). Interestingly, while all IncF plasmids tend to cluster together in our network (Fig. 5b), they were

separated into two distinct modules (1 & 3) (Fig. 5a). Beyond sharing the replicon type, the 2 plasmid modules also commonly encode relaxases belonging to the MOBF family (Fig. S5b). However, the modules differ in numbers of member plasmids, and module 1 is the larger of the two and the largest module in the network, consisting of 94 plasmids; in comparison, module 3 has 44 plasmids. The sizes of the member plasmids differed significantly ( $P = 0.01$ , Mann-Whitney U Test) between modules 1 (mean = 117.4 Kb; median = 119.1 Kb) and 3 (mean = 100.2 Kb; median = 75.1 Kb). The 2 modules also have differing host ranges: while most of the module 1 plasmids are carried by ST131 *E. coli* (70/94, 74.5%), the 2 most common module 3 hosts were ST38 (16/44, 36.4%) and ST744 (5/44, 11.4%) (Fig. 5c). The 2 modules also vary in their associations with specific ESBL genotypes. While module 1 plasmids are highly enriched in *bla*<sub>CTX-M-15</sub> ( $P = 2.88 \times 10^{-6}$ , Chi-Square goodness of fit) and *bla*<sub>CTX-M-27</sub> ( $P = 4.64 \times 10^{-13}$ , Chi-Square goodness of fit) genes, module 3 was enriched in *bla*<sub>CTX-M-55</sub> ( $P = 3.16 \times 10^{-13}$ , Chi-Square goodness of fit) and *bla*<sub>CTX-M-14</sub> ( $P = 2.47 \times 10^{-10}$ , Chi-Square goodness of fit) (Fig. S5c). Notably, while *bla*<sub>CTX-M-15</sub> overall and within module 2 was predominantly associated with *ISEscp1*, the gene was primarily (64.3%, 9/14) associated with *IS26* within module 1. Analysis of the module 1 pangenome revealed the genetic variability within this group, devoid of a core (present in >99% of plasmids) set among the 1,092 total encoded genes (Fig. S6a). However, the majority of plasmids within this module (92.6%, 87/94) were found to encode the *ccdB/ccdA* toxin/antitoxin pair. Moreover, yet another toxin/antitoxin pair, *pemK/pemI*, was commonly (85.1%, 80/94) encoded within this module. Similarly, the genetic content of the module 3 plasmids was highly variable, lacking core genes among the 1,109 total coding sequences (Fig. S6b). Plasmid addiction systems were also identified in this module, with the *vapC/vapB* and *pemK/pemI* toxin/antitoxin pairs encoded in 21 (47.7%) and 13 (29.5%) of the member plasmids. These findings were further corroborated through our functional annotation of the encoded genes and GO term enrichment analysis within plasmid modules. Both modules 1 and 3 were significantly enriched in genes involved in conjugation ( $P = 8.85 \times 10^{-197}$  and  $P = 2.34 \times 10^{-158}$ , respectively) and plasmid maintenance ( $P = 1.63 \times 10^{-179}$  and  $P = 2.89 \times 10^{-16}$ , respectively), relative to other plasmid modules in our network. Taken together, the mobilizable nature of these 2 modules in addition to the enrichment of plasmid maintenance mechanisms likely underlie the widespread and stable presence of such plasmids within the diverse clinical *E. coli* population.

## DISCUSSION

The spread of ESBLs among clinical *E. coli* isolates has been rapid, and the rate of ESBL carriage among hospital-associated infections has been on the rise (4, 6, 7). This spread is primarily facilitated by the association of CTX-M family of ESBLs with MGEs, particularly transposable elements and plasmids (5). Here, we conducted an in-depth characterization of clinical ESBL *E. coli* isolates collected from a single tertiary care hospital, with a particular focus on the epidemiology of ESBLs and the MGEs underlying the spread of the resistance genes. We identified 8 distinct ESBLs within our set of 149 isolates, with large predominance of *bla*<sub>CTX-M-15</sub>, *bla*<sub>CTX-M-27</sub>, *bla*<sub>CTX-M-14</sub>, and *bla*<sub>CTX-M-55</sub> (Fig. 1b). This is mostly in agreement with prior reports (5); however, *bla*<sub>CTX-M-55</sub> has been primarily associated with animal reservoirs in Asia (41), and to our knowledge, its prevalence among human clinical *E. coli* isolates in North America has not been reported before. Interestingly, the 4 most common ESBL genes vary vastly in their genetic origins: while *bla*<sub>CTX-M-15</sub> is predominantly encoded in bacterial chromosomes, plasmids are the most common carriers of *bla*<sub>CTX-M-27</sub> and *bla*<sub>CTX-M-55</sub>, and *bla*<sub>CTX-M-14</sub> is split near-evenly between the two DNA types (Table S2). The reasons behind such contrasting distributions in genetic origins are unknown. Globally, *bla*<sub>CTX-M-15</sub> is the most predominant ESBL variant in most regions, with certain exceptions where the predominance of *bla*<sub>CTX-M-14</sub> is observed instead (5). *bla*<sub>CTX-M-27</sub> and *bla*<sub>CTX-M-55</sub> are not as common; however, their prevalence has been on the rise recently (5). Transfer of genes between plasmids and chromosomes via transposable elements is well established, and it has been suggested that over long periods of time plasmidic genes that are beneficial to the bacterial host are transferred to



the chromosome (42–44). Thus, it may be speculated that varying prevalence of the ESBLs and the long-term chromosomal capture of plasmidic genes may explain the observed trends in their genetic origins; however, further investigation is necessary to test this hypothesis.

The commonplace transfer of ESBLs between plasmids and chromosomes is further demonstrated by identification of the resistance genes in conserved genetic contexts in both chromosomal and plasmidic contigs; presence of transposases within these conserved windows further supports their mobilizable nature. *ISEcp1* was the most common ESBL-associated transposase in our set (Fig. 3a to c) and more broadly (45). Beyond mediating mobilization, *ISEcp1* also serves as a promoter for the expression of the downstream ESBLs (46–49). Another prevalent ESBL-associated transposase in our isolate collection was *IS26*, which was found upstream of both *bla*<sub>CTX-M-15</sub> and *bla*<sub>CTX-M-27</sub> (Fig. 3d-f). The identified *IS26-bla*<sub>CTX-M-15</sub>- $\Delta$ Tn2 has been reported before, and this genetic configuration was suggested to drive the amplification of *bla*<sub>CTX-M-15</sub> as part of the mechanism engendering non-carbapenemase carbapenem-resistance in *Enterobacteriales* (35). We observed a similar instance of duplication of the *IS26-bla*<sub>CTX-M-15</sub>- $\Delta$ Tn2 cassette in one of the plasmids (Fig. 3d). We also observed putative *IS26*-mediated duplication of *bla*<sub>CTX-M-27</sub> (Fig. 3e) and *ISEcp1*-mediated amplifications of *bla*<sub>CTX-M-14</sub> (Fig. S2b) and *bla*<sub>CTX-M-55</sub> (Fig. 3b); however, the clinical importance of these gene amplification events could not be established.

Plasmids are the primary elements of horizontal spread of ESBLs. Indeed, we identified a large network of plasmid sharing between phylogenetically distant isolates (Fig. 4b), including instances of within- and between-patient ESBL plasmid sharing (Fig. S4a and c). The highly variable genetic architecture of plasmids has been noted before (50), and extensive variations in encoded genes have been reported even for groups of environmentally-related plasmids (39). Similarly, our plasmid set also shows extensive sequence diversity (Fig. S4d). Such variability impedes the efficient tracking of plasmid groups within bacterial populations and identification of associated genetic patterns. To circumvent these challenges, we implemented a recently reported ANI-based network analysis of plasmids (40), which allowed us to identify clusters of circulating plasmids within the given *E. coli* population and determine the plasmid modules primarily responsible dissemination of ESBLs within this catchment area. We identified the enrichments of *bla*<sub>CTX-M-15</sub> in module 6, consisting of IncI plasmids occupying a wide host range, and module 1, comprising IncF plasmids mainly restricted to ST131 *E. coli*. However, while *bla*<sub>CTX-M-15</sub> was primarily found downstream of the *ISEcp1* transposase within module 6, the gene was mostly found in *IS26*-encoding genetic cassettes in module 1, suggesting that the 2 plasmid groups constitute 2 distinct *bla*<sub>CTX-M-15</sub> dissemination routes within the clinical *E. coli* population. IncI plasmids are described predominantly in European poultry *E. coli* isolates and have been primarily associated with the *bla*<sub>CTX-M-1</sub> spread (51–55). However, IncI plasmids carrying *bla*<sub>CTX-M-15</sub> have been previously identified in both human and animal *E. coli* isolates (36, 56). Moreover, recombination events involving *bla*<sub>CTX-M-15</sub> carried by IncI plasmids have been suggested to underlie the emergence of novel, hybrid CTX-M beta-lactamases (57). Similarly, module 11, consisting of IncB family of plasmids, was found to be enriched in *bla*<sub>CTX-M-14</sub> genes. IncB family, also labeled as IncO, are less prevalent among the ESBL *E. coli* population but have been reported to carry ESBLs (55, 58, 59); however, to our knowledge, this is the first reported instance of IncB/O plasmid-encoded *bla*<sub>CTX-M-14</sub>. Importantly, although we identified significant enrichment of *bla*<sub>CTX-M-14</sub> in IncB/O plasmids, the corresponding module 11 comprises only 8 plasmids, and as such the generalizability of this finding necessitates further investigations.

Previous reports establish IncF plasmids as the primary disseminators of ESBLs, most notably *bla*<sub>CTX-M-15</sub> and *bla*<sub>CTX-M-14</sub> (5, 15, 52, 59–65). Similarly, in our cohort, IncF plasmids were found to be significantly enriched in ESBLs relative to other plasmid families (Fig. S5c). Furthermore, our network analysis of plasmids indicated that the IncF plasmids exists within at least 2 major lineages (modules 1 & 3) with varying ESBL profiles and host preferences (Fig. 5b and Fig. S5c). While the association between

ST131 *E. coli* and IncF plasmids has been noted (19, 60, 61, 66), only one of the IncF lineages in our cohort, module 1, was predominantly present in ST131 hosts. Module 3, despite being the smaller of the 2 IncF modules, had a broader host range, including 16 different STs (compared to 13 STs among the module 1 hosts), most commonly (36.4%) isolated from ST38 hosts. The 2 modules encompassed high gene content variability (Fig. S6); however, mobilization elements and plasmid addiction systems were commonly found within both plasmid modules, suggesting that there is a relatively constant backbone structure that includes elements essential for propagation and maintenance of these plasmids, while the accessory components of the plasmids undergo rapid and substantial diversification. Indeed, a recent genomic analysis of environmental and livestock IncF plasmids also identified a stable backbone structure within groups of related plasmids as well as a largely variable accessory sets of genes (39). Such diversity in the accessory gene content is suggested to be engendered by niche adaptations; however, there is a need for further investigations demonstrating the emergence of such variations and their roles in plasmid biology within variable environments.

Although we have performed comprehensive profiling of a large cohort of ESBL-producing strains, we acknowledge important study limitations. For one, our plasmid analysis only considered circular contigs within 1M bp. While such inclusion criteria would minimize the incidences of false positives (i.e., chromosomal sequences identified as plasmidic), it would omit any linear contigs of plasmidic origin. Thus, our plasmid analysis almost certainly didn't capture the entire plasmidome of our sample set. However, given our hybrid sequencing and assembly approaches, most of the assembled contigs (72.0%, 601/835) could be accurately assigned to be of either chromosomal or plasmidic origins, and the majority of unassigned contigs were below 10,000 bp in length (median of 5,937 bp) (Fig. S7). Furthermore, the genetic nature (i.e., chromosome or plasmid) of 93.7% (164/175) of the ESBL-encoding contigs in our set could be determined. Given our aim to investigate the agents of ESBL spread, plasmid modules not associated with ESBL carriage were left underexplored. This was particularly true of the small plasmids, such as those found within modules 4 and 5, which were highly conserved and found within a diverse host range. The biological significance of these plasmids warrants further investigations, and our extensive sequencing and gene enrichment data (Data Set S1, Sheet B) will facilitate such future explorations. Furthermore, given that all bacterial isolates in the study originated from a single hospital system, future investigations focusing on more diverse geographical settings are necessary to determine the generalizability of our findings. Lastly, we also explicitly focused on clinical ESBL *E. coli* isolates given the growing importance of these organisms; as such, the broader implications of our findings regarding the nature and epidemiology of the described MGEs in non-ESBL clinical isolates or community-associated *E. coli* strains need additional validation.

In conclusion, we conducted an in-depth genomic analysis of infectious ESBL *E. coli* isolates from a single tertiary care hospital. Our analysis revealed the major ESBLs in circulation within the given population and identified MGEs associated with major resistance genes. Our high-quality genomic assemblies enabled us to characterize a nearly complete set of plasmids and detect clusters of related plasmids that are primarily responsible for the spread of ESBLs within the clinical *E. coli* population. Given the global ubiquity of ESBL *E. coli* colonization (1), similar network analyses of non-clinical isolates are warranted to investigate the spread of the identified plasmid groups outside of nosocomial settings.

## MATERIALS AND METHODS

**Sample collection.** All specimens and data used in this study were retrospective and collected during routine clinical care; as a result, this study was approved by the Washington University in St. Louis Human Research Protection Office with a waiver of informed consent.

The study was conducted at a 1250-bed, tertiary care hospital in St. Louis, Missouri. The hospital's Medical Informatics database was queried to retrospectively identify all blood and urine cultures positive

for “ESBL-like” *E. coli* from 2016–2019. Patients with urine and/or blood cultures positive for ESBL-like *E. coli* were included in the study cohort if they met the following criteria:

1. Admitted to a medicine, oncology, or medical ICU ward during the study period.
2. ESBL *E. coli* isolate was collected from a clinical specimen within 24 h prior to admission to the study ward through 24 h after discharge from the study ward.

For patients with >1 blood or urine specimens positive for *E. coli* during the study period, specimens of the same type (i.e., urine or blood) collected within 14 days of a prior positive specimen were excluded.

ESBL-like was defined as phenotypic susceptibility suggestive of an ESBL-producing strain: resistant to first-generation cephalosporins, resistant to at least one third-generation cephalosporin (with ceftazidime and ceftriaxone being routinely tested), and susceptible to cephamycins (with cefotetan being routinely tested). Antibiotic susceptibility testing (AST) was performed on all isolates selected for inclusion in the study cohort.

AST was performed on all isolates according to the Clinical and Laboratory Standards Institute M100 document. In short, an 18-h culture of each organism on tryptic soy agar with 5% sheep's blood (Hardy Diagnostics) was used to make a 0.5 McFarland standard in saline. This suspension was inoculated on Mueller-Hinton agar (Hardy Diagnostics) in such a way to create a lawn of growth. Antibiotic disks (Hardy Diagnostics and BD, Franklin) were dropped on the Mueller-Hinton agar and incubated for 16–18 h. Each organism was tested against the following antibiotics: ampicillin (10  $\mu$ g), cefazolin (30  $\mu$ g), cefotetan (30  $\mu$ g), ceftazidime (30  $\mu$ g), ceftriaxone (30  $\mu$ g), cefepime (30  $\mu$ g), meropenem (10  $\mu$ g), ertapenem (10  $\mu$ g), imipenem (10  $\mu$ g), ceftriaxone-tazobactam (30  $\mu$ g/10  $\mu$ g), ceftazidime-avibactam (30  $\mu$ g/20  $\mu$ g), ampicillin-sulbactam (20  $\mu$ g), ciprofloxacin (5  $\mu$ g), doxycycline (30  $\mu$ g), gentamicin (10  $\mu$ g), amikacin (30  $\mu$ g), nitrofurantoin (300  $\mu$ g), cefiderocol (30  $\mu$ g), piperacillin-tazobactam (110  $\mu$ g), fosfomicin (200  $\mu$ g), colistin (10  $\mu$ g), aztreonam (30  $\mu$ g), trimethoprim-sulfamethoxazole (23.75  $\mu$ g/1.25  $\mu$ g), and tigecycline (15  $\mu$ g). Zone sizes were measured using a metric ruler, and interpretations were given based on the M100 guidelines (67).

**Whole-genome sequencing and *de novo* genome assembly.** Where appropriate, the parameters used for the computational tools are provided parenthetically. Isolates were grown overnight on tryptic soy agar with 5% sheep's blood (Hardy Diagnostics), and colonies were collected and resuspended in deionized water. Total genomic DNA from each suspension was isolated using the QIAamp BiOstic Bacteremia DNA Kit (Qiagen) and quantified using the Qubit dsDNA HS and BR Assay Kits (Invitrogen). For each isolate, 0.5 ng of the extracted DNA was used as the input for Illumina library preparation using the Nextera kit (Illumina) (68). Libraries were pooled and sequenced on the NovaSeq 6000 platform (Illumina) to obtain  $2 \times 150$  bp reads. The reads were demultiplexed by index pair, quality trimmed by Trimmomatic (v0.38, SLIDINGWINDOW:4:20, LEADING:10, TRAILING:10, MINLEN:60) (69), and decontaminated using Deconseq (v4.3, -dbs href38) (70).

All isolates were also sequenced using the Oxford Nanopore Technologies long-read sequencing platform. Total genomic DNA was extracted as before, but the lysates in PowerBead Tubes were vortexed only for 90 s to yield high molecular weight DNA fragments. For each isolate, 1  $\mu$ g of DNA was used to prepare sequencing libraries using the NEBNext kit (New England BioLabs) and sequenced using the MinION platform. The output fastq files were filtered using Filtlong (v2.0, -min\_length 1000, -keep\_percent 95, -target\_bases 500000000) (<https://github.com/rwvick/Filtlong>) and used for *de novo* genome assembly using Flye (v2.8.1, -plasmids) (71). The resulting assemblies were further corrected with the processed Illumina reads using Pilon (72). The resulting contigs were determined to be chromosomal if their length exceeded 1M bp, and circular contigs <1M bp in length were assigned to be plasmidic.

**Phylogenetic analysis.** Assembled contigs were annotated using Prokka (v1.14.5, -mincontiglen 200, -force, -rnammer) (73). The resulting gff files were used to identify the core genome set and construct a corresponding alignment using Roary (v3.13.0, -g 500000, -e) (74). The core genome alignment was used to construct a maximum likelihood tree with FastTree (v2.1.10, -nt, -gtr) (75). The resulting newick file was visualized in iTOL (76). *In silico* MLST was performed via the MLST tool (v2.19, -scheme *ecoli\_4*) (<https://github.com/tseemann/mlst>) using the Achtman scheme. The pairwise SNP counts were generated by using the core genome alignment as the input for snp-dists (v0.8.2) (<https://github.com/tseemann/snp-dists>). Within groups of highly related isolates (as determined through the core genome SNP counts), the processed Illumina reads for each isolate were mapped to a common reference (i.e., assembled complete chromosomal contig of one of the isolates) using snippy (v4.4.3) (<https://github.com/tseemann/snippy>); the resulting alignment was similarly used as the input for snp-dists (v0.8.2) to determine the pairwise SNP counts.

**ESBL identification.** Encoded ESBLs were identified using AMRFinder (v3.10.16) on the Prokka-generated gff files. Only for the determination of the genetic origins (chromosomal or plasmidic) of the identified ESBLs, the linear contigs <1M bp in size were assigned as putative plasmids if the corresponding isolate chromosomal contig was complete (i.e., circular); however, such putatively plasmidic contigs were not considered for the plasmid sharing and ANI-based network analyses. Transposases neighboring ESBLs were first annotated through Prokka and subsequently validated by aligning the protein sequences against the ISfinder database (77). The analysis and visualization of the genomic contexts of ESBL genotypes was done using Easyfig (v2.2.2) (78).

**Plasmid typing and functional annotation.** For our plasmid analysis, we only included circular contigs <1M bp in size, resulting in 446 plasmidic contigs. Replicon typing of the plasmid sequences was done using PlasmidFinder (v2.0.1) (79) using the *Enterobacteriales* database with 95% minimum identity and 60% minimum coverage. The encoded relaxases were identified and classified through MOBscan (80) using the Prokka-generated faa files. The functional annotation of the plasmid-encoded genes was done using Blast2GO (81) using the default parameters. For the analysis of plasmid sharing, pairs of

plasmids were aligned to each other in all possible, non-redundant combinations using the default BLASTn parameters.

**Plasmid cluster analysis.** The plasmid clustering method was first reported elsewhere (40) and was used here with modifications. The pairwise ANI values were calculated for all nonredundant plasmid combinations using fastANI (v1.33) (82) with the following parameters: fragLen 250 and minFraction 0.5. A custom Python script was used to remove self-comparisons and average the values for reciprocal pairs. The resulting pairwise ANI values were transformed to edge weights to be used in the subsequent plasmid network as follows:

$$\text{Edge weight} = \frac{1}{1 + 100(1 - \text{ANI}/100)} \quad (1)$$

The plasmid network was constructed using the linear logarithmic version of ForceAtlas2 (83) within Gephi. In this network, plasmids were represented as nodes, and pairs of nodes with non-zero ANI scores were linked together with edges weights calculated as above (Equation 1). ForceAtlas2 was used with the following parameters: approximation 1.2, scaling 0.1, gravity 1.0, and edge weight influence 1.0. The plasmid clusters within the spatialized network were identified by using the modularity optimization algorithm built within Gephi (84, 85). Lastly, modules with fewer than 4 plasmids were excluded.

**Statistical analysis.** The enrichment of genes and GO terms in plasmid modules and sequence types was done using the Chi-Square goodness of fit test. In each instance, the expected values were calculated to be proportional to the number of plasmids with the tested module relative to the total number of plasmids. The observed and expected values were used as inputs for the “chisquare” function within the SciPy library in Python. The resulting *P*-values were adjusted for multiple comparisons using the Bonferroni method in the “p.adjust” function within the stats library in R. The enrichment of ESBLs in STs, and ESBLs and ARGs in IncF plasmids were also tested as described.

**Data availability.** All isolate assemblies as well as the sequencing data from Illumina and Oxford Nanopore Technologies platforms are available in NCBI GenBank under BioProject accession no. [PRJNA824420](https://www.ncbi.nlm.nih.gov/bioproject/PRJNA824420), which includes short- (accession no. [SRR18678975-9123](https://www.ncbi.nlm.nih.gov/sra/SRR18678975-9123)) and long-read (accession no. [SRR18681602-750](https://www.ncbi.nlm.nih.gov/sra/SRR18681602-750)) SRA, as well as the BioSample hybrid assemblies (accession no. [SAMN27404312-460](https://www.ncbi.nlm.nih.gov/biosample/SAMN27404312-460)) for all 149 isolates in the study.

## SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

**DATA SET S1**, XLSX file, 0.8 MB.

**FIG S1**, TIF file, 0.4 MB.

**FIG S2**, TIF file, 1 MB.

**FIG S3**, JPG file, 0.3 MB.

**FIG S4**, TIF file, 1.7 MB.

**FIG S5**, TIF file, 2.5 MB.

**FIG S6**, TIF file, 0.1 MB.

**FIG S7**, TIF file, 0.3 MB.

**TABLE S1**, DOCX file, 0.01 MB.

**TABLE S2**, DOCX file, 0.01 MB.

## ACKNOWLEDGMENTS

We thank members of the Dantas lab for helpful feedback on this work and manuscript. We thank the Edison Family Center for Genome Sciences and Systems Biology staff (Eric Martin, Brian Koebebe, MariaLynn Crosby, and Jessica Hoisington-López) for their expertise and support in sequencing and high-throughput computing.

This work was supported in part by awards to G.D. through the National Institute of Allergy and Infectious Diseases of the NIH (grant numbers U01AI123394 and R01AI155893); the Agency for Healthcare Research and Quality (grant number R01HS027621); and the Congressionally Directed Medical Research Program of the US Department of Defense (grant number W81XWH1810225). This work was supported in part by an award to C.L. through the Centers for Disease Control and Prevention (grant number U01CK000587).

The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

C.L., E.R.D., D.A.R., and G.D. conceived the project. M.A.W., K.A.R., C.-A.D.B., and E.R.D. collected the isolates. M.A.W., K.A., and C.E.M. cultured the isolates. B.M. performed the sequencing and genomic analysis. B.M., M.A.W., K.A.R., K.A., C.E.M., D.A.R., C.-A.D.B., C.L., E.R.D., and G.D. analyzed the data and wrote the manuscript.

We declare no competing interests.

## REFERENCES

1. Woerther PL, Burdet C, Chachaty E, Andremont A. 2013. Trends in human fecal carriage of extended-spectrum beta-lactamases in the community: toward the globalization of CTX-M. *Clin Microbiol Rev* 26:744–758. <https://doi.org/10.1128/CMR.00023-13>.
2. Maslikowska JA, Walker SAN, Elligsen M, Mittmann N, Palmay L, Daneman N, Simor A. 2016. Impact of infection with extended-spectrum beta-lactamase-producing *Escherichia coli* or *Klebsiella* species on outcome and hospitalization costs. *J Hosp Infect* 92:33–41. <https://doi.org/10.1016/j.jhin.2015.10.001>.
3. D'Andrea MM, Arena F, Pallecchi L, Rossolini GM. 2013. CTX-M-type beta-lactamases: a successful story of antibiotic resistance. *Int J Med Microbiol* 303:305–317. <https://doi.org/10.1016/j.ijmm.2013.02.008>.
4. Doi Y, Iovleva A, Bonomo RA. 2017. The ecology of extended-spectrum beta-lactamases (ESBLs) in the developed world. *J Travel Med* 24: S44–S51. <https://doi.org/10.1093/jtm/taw102>.
5. Bevan ER, Jones AM, Hawkey PM. 2017. Global epidemiology of CTX-M beta-lactamases: temporal and geographical shifts in genotype. *J Antimicrob Chemother* 72:2145–2155. <https://doi.org/10.1093/jac/dkx146>.
6. Lob SH, Nicolle LE, Hoban DJ, Kazmierczak KM, Badal RE, Sahn DF. 2016. Susceptibility patterns and ESBL rates of *Escherichia coli* from urinary tract infections in Canada and the United States, SMART 2010–2014. *Diagn Microbiol Infect Dis* 85:459–465. <https://doi.org/10.1016/j.diagmicrobio.2016.04.022>.
7. Denisuk AJ, Lagace-Wiens PRS, Pitout JD, Mulvey MR, Simner PJ, Taylor F, Karlowsky JA, Hoban DJ, Adam HJ, Zhanel GG, Zhanel GG, Hoban DJ, Adam HJ, Karlowsky JA, Baxter MR, Nichol KA, Lagace-Wiens PRS, Walkty A, on behalf of the Canadian Antimicrobial Resistance Alliance (CARA). 2013. Molecular epidemiology of extended-spectrum beta-lactamase-, AmpC beta-lactamase- and carbapenemase-producing *Escherichia coli* and *Klebsiella pneumoniae* isolated from Canadian hospitals over a 5 year period: CANWARD 2007–11. *J Antimicrob Chemother* 68:i57–65. <https://doi.org/10.1093/jac/dkt027>.
8. Agyekum A, Fajardo-Lubián A, Ansong D, Partridge SR, Agbenyega T, Iredell JR. 2016. blaCTX-M-15 carried by IncF-type plasmids is the dominant ESBL gene in *Escherichia coli* and *Klebsiella pneumoniae* at a hospital in Ghana. *Diagn Microbiol Infect Dis* 84:328–333. <https://doi.org/10.1016/j.diagmicrobio.2015.12.010>.
9. Irrgang A, Falgenhauer L, Fischer J, Ghosh H, Guiral E, Guerra B, Schmogger S, Imirzalioglu C, Chakraborty T, Hammerl JA, Käsbohrer A. 2017. CTX-M-15-producing *E. coli* isolates from food products in Germany are mainly associated with an IncF-Type plasmid and belong to two predominant clonal *E. coli* lineages. *Front Microbiol* 8:2318. <https://doi.org/10.3389/fmicb.2017.02318>.
10. Markovska R, Schneider I, Ivanova D, Mitov I, Bauernfeind A. 2014. Predominance of IncL/M and IncF plasmid types among CTX-M-ESBL-producing *Escherichia coli* and *Klebsiella pneumoniae* in Bulgarian hospitals. *APMIS* 122: 608–615. <https://doi.org/10.1111/apm.12204>.
11. Madec JY, Haenni M. 2018. Antimicrobial resistance plasmid reservoir in food and food-producing animals. *Plasmid* 99:72–81. <https://doi.org/10.1016/j.plasmid.2018.09.001>.
12. Koraimann G. 2018. Spread and persistence of virulence and antibiotic resistance genes: a ride on the F plasmid conjugation module. *EcoSal Plus* 8 <https://doi.org/10.1128/ecosalplus.ESP-0003-2018>.
13. Lopatkin AJ, Meredith HR, Srimani JK, Pfeiffer C, Durrett R, You L. 2017. Persistence and reversal of plasmid-mediated antibiotic resistance. *Nat Commun* 8:1689. <https://doi.org/10.1038/s41467-017-01532-1>.
14. de Been M, Lanza VF, de Toro M, Scharringa J, Dohmen W, Du Y, Hu J, Lei Y, Li N, Tooming-Klunderud A, Heederik DJJ, Fluit AC, Bonten MJM, Willems RJL, de la Cruz F, van Schaik W. 2014. Dissemination of cephalosporin resistance genes between *Escherichia coli* strains from farm animals and humans by specific plasmid lineages. *PLoS Genet* 10:e1004776. <https://doi.org/10.1371/journal.pgen.1004776>.
15. Marcade G. 2009. Replicon typing of plasmids in *Escherichia coli* producing extended-spectrum beta-lactamases. *J Antimicrob Chemother* 63: 67–71. <https://doi.org/10.1093/jac/dkn428>.
16. Hopkins KL, Liebana E, Villa L, Batchelor M, Threlfall EJ, Carattoli A. 2006. Replicon typing of plasmids carrying CTX-M or CMY beta-lactamases circulating among *Salmonella* and *Escherichia coli* isolates. *Antimicrob Agents Chemother* 50:3203–3206. <https://doi.org/10.1128/AAC.00149-06>.
17. Zurfluh K, Glier M, Hachler H, Stephan R. 2015. Replicon typing of plasmids carrying blaCTX-M-15 among *Enterobacteriaceae* isolated at the environment, livestock and human interface. *Sci Total Environ* 521–522: 75–78. <https://doi.org/10.1016/j.scitotenv.2015.03.079>.
18. Baraniak A, Fiett J, Sulikowska A, Hryniewicz W, Gniadkowski M. 2002. Countrywide spread of CTX-M-3 extended-spectrum beta-lactamase-producing microorganisms of the family *Enterobacteriaceae* in Poland. *Antimicrob Agents Chemother* 46:151–159. <https://doi.org/10.1128/AAC.46.1.151-159.2002>.
19. Kondratyeva K, Salmon-Divon M, Navon-Venezia S. 2020. Meta-analysis of pandemic *Escherichia coli* ST131 plasmidome proves restricted plasmid-clade associations. *Sci Rep* 10:36. <https://doi.org/10.1038/s41598-019-56763-7>.
20. Brolund A, Rajer F, Giske CG, Melefos Ö, Titelman E, Sandegren L. 2019. Dynamics of resistance plasmids in extended-spectrum-beta-lactamase-producing *Enterobacteriaceae* during postinfection colonization. *Antimicrob Agents Chemother* 63:e02201-18. <https://doi.org/10.1128/AAC.02201-18>.
21. Girlich D, Poirel L, Carattoli A, Kempf I, Lartigue M-F, Bertini A, Nordmann P. 2007. Extended-spectrum beta-lactamase CTX-M-1 in *Escherichia coli* isolates from healthy poultry in France. *Appl Environ Microbiol* 73: 4681–4685. <https://doi.org/10.1128/AEM.02491-06>.
22. Woodford N, Carattoli A, Karisik E, Underwood A, Ellington MJ, Livermore DM. 2009. Complete nucleotide sequences of plasmids pEK204, pEK499, and pEK516, encoding CTX-M enzymes in three major *Escherichia coli* lineages from the United Kingdom, all belonging to the international O25:H4-ST131 clone. *Antimicrob Agents Chemother* 53:4472–4482. <https://doi.org/10.1128/AAC.00688-09>.
23. Partridge SR, Zong Z, Iredell JR. 2011. Recombination in IS26 and Tn2 in the evolution of multiresistance regions carrying blaCTX-M-15 on conjugative IncF plasmids from *Escherichia coli*. *Antimicrob Agents Chemother* 55:4971–4978. <https://doi.org/10.1128/AAC.00025-11>.
24. Novais A, Cantón R, Moreira R, Peixe L, Baquero F, Coque TM. 2007. Emergence and dissemination of *Enterobacteriaceae* isolates producing CTX-M-1-like enzymes in Spain are associated with IncFII (CTX-M-15) and broad-host-range (CTX-M-1, -3, and -32) plasmids. *Antimicrob Agents Chemother* 51:796–799. <https://doi.org/10.1128/AAC.01070-06>.
25. Moodley A, Guardabassi L. 2009. Transmission of IncN plasmids carrying blaCTX-M-1 between commensal *Escherichia coli* in pigs and farm workers. *Antimicrob Agents Chemother* 53:1709–1711. <https://doi.org/10.1128/AAC.01014-08>.
26. Deng Y, He L, Chen S, Zheng H, Zeng Z, Liu Y, Sun Y, Ma J, Chen Z, Liu J-H. 2011. F33:A-B- and F2:A-B- plasmids mediate dissemination of rmtB-blaCTX-M-9 group genes and rmtB-qepA in *Enterobacteriaceae* isolates from pets in China. *Antimicrob Agents Chemother* 55:4926–4929. <https://doi.org/10.1128/AAC.00133-11>.
27. Nishida K, Mihara K, Takino T, Nakane S, Takakura Y, Hashida M, Sezaki H. 1991. Hepatic disposition characteristics of electrically charged macromolecules in rat in vivo and in the perfused liver. *Pharm Res* 8:437–444. <https://doi.org/10.1023/A:1015886708598>.
28. Coque TM, Novais A, Carattoli A, Poirel L, Pitout J, Peixe L, Baquero F, Cantón R, Nordmann P. 2008. Dissemination of clonally related *Escherichia coli* strains expressing extended-spectrum beta-lactamase CTX-M-15. *Emerg Infect Dis* 14:195–200. <https://doi.org/10.3201/eid1402.070350>.
29. Wirth T, Falush D, Lan R, Colles F, Mensa P, Wieler LH, Karch H, Reeves PR, Maiden MCJ, Ochman H, Achtman M. 2006. Sex and virulence in *Escherichia coli*: an evolutionary perspective. *Mol Microbiol* 60:1136–1151. <https://doi.org/10.1111/j.1365-2958.2006.05172.x>.



30. Nicolas-Chanoine MH, Bertrand X, Madec JY. 2014. *Escherichia coli* ST131, an intriguing clonal group. Clin Microbiol Rev 27:543–574. <https://doi.org/10.1128/CMR.00125-13>.
31. Banerjee R, Johnson JR. 2014. A new clone sweeps clean: the enigmatic emergence of *Escherichia coli* sequence type 131. Antimicrob Agents Chemother 58:4997–5004. <https://doi.org/10.1128/AAC.02824-14>.
32. Yang Y-M, Osawa K, Kitagawa K, Hosoya S, Onishi R, Ishii A, Shirakawa T, Hirai I, Kuntaman K, Tanimoto H, Shigemura K, Fujisawa M. 2021. Differential effects of chromosome and plasmid blaCTX-M-15 genes on antibiotic susceptibilities in extended-spectrum beta-lactamase-producing *Escherichia coli* isolates from patients with urinary tract infection. Int J Urol 28: 623–628. <https://doi.org/10.1111/iju.14498>.
33. Zheng W, Yue M, Zhang J, Ruan Z. 2021. Coexistence of two blaCTX-M-14 genes in a blaNDM-5-carrying multidrug-resistant *Escherichia coli* strain recovered from a bloodstream infection in China. J Glob Antimicrob Resist 26:11–14. <https://doi.org/10.1016/j.jgar.2021.05.002>.
34. Hamamoto K, Ueda S, Toyosato T, Yamamoto Y, Hirai I. 2016. High prevalence of chromosomal blaCTX-M-14 in *Escherichia coli* isolates possessing blaCTX-M-14. Antimicrob Agents Chemother 60:2582–2584. <https://doi.org/10.1128/AAC.00108-16>.
35. Shropshire WC, Aitken SL, Pifer R, Kim J, Bhatti MM, Li X, Kalia A, Galloway-Peña J, Sahasrabhojane P, Arias CA, Greenberg DE, Hanson BM, Shelburne SA. 2021. IS26-mediated amplification of blaOXA-1 and blaCTX-M-15 with concurrent outer membrane porin disruption associated with de novo carbapenem resistance in a recurrent bacteraemia cohort. J Antimicrob Chemother 76:385–395. <https://doi.org/10.1093/jac/dkaa447>.
36. Smet A, Van Nieuwerburgh F, Vandekerckhove TTM, Martel A, Deforce D, Butaye P, Haesebrouck F. 2010. Complete nucleotide sequence of CTX-M-15-plasmids from clinical *Escherichia coli* isolates: insertional events of transposons and insertion sequences. PLoS One 5:e11202. <https://doi.org/10.1371/journal.pone.0011202>.
37. Matsuo N, Nonogaki R, Hayashi M, Wachino J-i, Suzuki M, Arakawa Y, Kawamura K. 2020. Characterization of bla CTX-M-27/F1:A2:B20 plasmids harbored by *Escherichia coli* sequence Type 131 sublineage C1/H30R isolates spreading among elderly Japanese in nonacute-care settings. Antimicrob Agents Chemother 64:e00202-20. <https://doi.org/10.1128/AAC.00202-20>.
38. Brolund A, Sandegren L. 2016. Characterization of ESBL disseminating plasmids. Infect Dis (Lond) 48:18–25. <https://doi.org/10.3109/23744235.2015.1062536>.
39. Matlock W, Chau KK, AbuOun M, Stubberfield E, Barker L, Kavanagh J, Pickford H, Gilson D, Smith RP, Gweon HS, Hoosdally SJ, Swann J, Sebra R, Bailey MJ, Peto TEA, Crook DW, Anjum MF, Read DS, Walker AS, Stoesser N, Shaw LP, REHAB consortium. 2021. Genomic network analysis of environmental and livestock F-type plasmid populations. ISME J 15: 2322–2335. <https://doi.org/10.1038/s41396-021-00926-w>.
40. Redondo-Salvo S, Fernández-López R, Ruiz R, Vielva L, de Toro M, Rocha EPC, Garcillán-Barcia MP, de la Cruz F. 2020. Pathways for horizontal gene transfer in bacteria revealed by a global map of their plasmids. Nat Commun 11:3602. <https://doi.org/10.1038/s41467-020-17278-2>.
41. Yang X, Liu W, Liu Y, Wang J, Lv L, Chen X, He D, Yang T, Hou J, Tan Y, Xing L, Zeng Z, Liu J-H. 2014. F33: A- B-, IncHI2/ST3, and IncI1/ST71 plasmids drive the dissemination of fosA3 and bla CTX-M-55/-14/-65 in *Escherichia coli* from chickens in China. Front Microbiol 5:688. <https://doi.org/10.3389/fmicb.2014.00688>.
42. Carroll AC, Wong A. 2018. Plasmid persistence: costs, benefits, and the plasmid paradox. Can J Microbiol 64:293–304. <https://doi.org/10.1139/cjm-2017-0609>.
43. Bergstrom CT, Lipsitch M, Levin BR. 2000. Natural selection, infectious transfer and the existence conditions for bacterial plasmids. Genetics 155: 1505–1519. <https://doi.org/10.1093/genetics/155.4.1505>.
44. Brockhurst MA, Harrison E. 2021. Ecological and evolutionary solutions to the plasmid paradox. Trends Microbiol 30: 534–543. <https://doi.org/10.1016/j.tim.2021.11.001>.
45. Zhao WH, Hu ZQ. 2013. Epidemiology and genetics of CTX-M extended-spectrum beta-lactamases in Gram-negative bacteria. Crit Rev Microbiol 39:79–101. <https://doi.org/10.3109/1040841X.2012.691460>.
46. Karim A, Poirel L, Nagarajan S, Nordmann P. 2001. Plasmid-mediated extended-spectrum beta-lactamase (CTX-M-3 like) from India and gene association with insertion sequence ISEcp1. FEMS Microbiol Lett 201: 237–241. <https://doi.org/10.1111/j.1574-6968.2001.tb10762.x>.
47. Cao V, Lambert T, Courvalin P. 2002. ColE1-like plasmid pIP843 of *Klebsiella pneumoniae* encoding extended-spectrum beta-lactamase CTX-M-17. Antimicrob Agents Chemother 46:1212–1217. <https://doi.org/10.1128/AAC.46.5.1212-1217.2002>.
48. Poirel L, Decusser JW, Nordmann P. 2003. Insertion sequence ISEcp1B is involved in expression and mobilization of a bla(CTX-M) beta-lactamase gene. Antimicrob Agents Chemother 47:2938–2945. <https://doi.org/10.1128/AAC.47.9.2938-2945.2003>.
49. Dhanji H, Patel R, Wall R, Doumith M, Patel B, Hope R, Livermore DM, Woodford N. 2011. Variation in the genetic environments of bla(CTX-M-15) in *Escherichia coli* from the faeces of travellers returning to the United Kingdom. J Antimicrob Chemother 66:1005–1012. <https://doi.org/10.1093/jac/dkr041>.
50. Acman M, van Dorp L, Santini JM, Balloux F. 2020. Large-scale network analysis captures biological features of bacterial plasmids. Nat Commun 11:2452. <https://doi.org/10.1038/s41467-020-16282-w>.
51. Borjesson S, Bengtsson B, Jernberg C, Englund S. 2013. Spread of extended-spectrum beta-lactamase producing *Escherichia coli* isolates in Swedish broilers mediated by an IncI plasmid carrying bla(CTX-M-1). Acta Vet Scand 55:3. <https://doi.org/10.1186/1751-0147-55-3>.
52. Rozwandowicz M, Brouwer MSM, Fischer J, Wagenaar JA, Gonzalez-Zorn B, Guerra B, Mevius DJ, Hordijk J. 2018. Plasmids carrying antimicrobial resistance genes in *Enterobacteriaceae*. J Antimicrob Chemother 73: 1121–1137. <https://doi.org/10.1093/jac/dkx488>.
53. Zurfluh K, Jakobi G, Stephan R, Hachler H, Nuesch-Inderbinen M. 2014. Replicon typing of plasmids carrying bla CTX-M-1 in *Enterobacteriaceae* of animal, environmental and human origin. Front Microbiol 5:555. <https://doi.org/10.3389/fmicb.2014.00555>.
54. Irrgang A, Hammerl JA, Falgenhauer L, Guiral E, Schmogger S, Imrzioliglu C, Fischer J, Guerra B, Chakraborty T, Käsbohrer A. 2018. Diversity of CTX-M-1-producing *E. coli* from German food samples and genetic diversity of the blaCTX-M-1 region on IncI1 ST3 plasmids. Vet Microbiol 221:98–104. <https://doi.org/10.1016/j.vetmic.2018.06.003>.
55. Leverstein-van Hall MA, Dierikx CM, Cohen Stuart J, Voets GM, van den Munckhof MP, van Essen-Zandbergen A, Platteel T, Fluit AC, van de Sande-Bruinsma N, Scharinga J, Bonten MJM, Mevius DJ, National ESB� surveillance group. 2011. Dutch patients, retail chicken meat and poultry share the same ESBL genes, plasmids and strains. Clin Microbiol Infect 17: 873–880. <https://doi.org/10.1111/j.1469-0691.2011.03497.x>.
56. Zong Z, Ginn AN, Dobiasova H, Iredell JR, Partridge SR. 2015. Different IncI1 plasmids from *Escherichia coli* carry ISEcp1-blaCTX-M-15 associated with different Tn2-derived elements. Plasmid 80:118–126. <https://doi.org/10.1016/j.plasmid.2015.04.007>.
57. Liu L, He D, Lv L, Liu W, Chen X, Zeng Z, Partridge SR, Liu J-H. 2015. blaCTX-M-1/9/1 hybrid genes may have been generated from blaCTX-M-15 on an IncI2 Plasmid. Antimicrob Agents Chemother 59:4464–4470. <https://doi.org/10.1128/AAC.00501-15>.
58. Li J, Li B, Ni Y, Sun J. 2015. Molecular characterization of the extended-spectrum beta-lactamase (ESBL)-producing *Shigella* spp. in Shanghai. Eur J Clin Microbiol Infect Dis 34:447–451. <https://doi.org/10.1007/s10096-014-2244-2>.
59. Diestra K, Juan C, Curiao T, Moyá B, Miró E, Oteo J, Coque TM, Pérez-Vázquez M, Campos J, Cantón R, Oliver A, Navarro F, Red Española de Investigación en Patología Infecciosa (REIPI), Spain. 2009. Characterization of plasmids encoding blaESBL and surrounding genes in Spanish clinical isolates of *Escherichia coli* and *Klebsiella pneumoniae*. J Antimicrob Chemother 63:60–66. <https://doi.org/10.1093/jac/dkn453>.
60. Novais A, Pires J, Ferreira H, Costa L, Montenegro C, Vuotto C, Donelli G, Coque TM, Peixe L. 2012. Characterization of globally spread *Escherichia coli* ST131 isolates (1991 to 2010). Antimicrob Agents Chemother 56: 3973–3976. <https://doi.org/10.1128/AAC.00475-12>.
61. Novais A, Viana D, Baquero F, Martínez-Botas J, Cantón R, Coque TM. 2012. Contribution of IncFII and broad-host IncA/C and IncN plasmids to the local expansion and diversification of phylogroup B2 *Escherichia coli* ST131 clones carrying blaCTX-M-15 and qnrS1 genes. Antimicrob Agents Chemother 56:2763–2766. <https://doi.org/10.1128/AAC.06001-11>.
62. Gonullu N, Aktas Z, Kayacan CB, Salcioglu M, Carattoli A, Yong DE, Walsh TR. 2008. Dissemination of CTX-M-15 beta-lactamase genes carried on Inc FI and FII plasmids among clinical isolates of *Escherichia coli* in a university hospital in Istanbul, Turkey. J Clin Microbiol 46:1110–1112. <https://doi.org/10.1128/JCM.01974-07>.
63. Lee MY, Ko KS, Kang C-I, Chung DR, Peck KR, Song J-H. 2011. High prevalence of CTX-M-15-producing *Klebsiella pneumoniae* isolates in Asian countries: diverse clones and clonal dissemination. Int J Antimicrob Agents 38:160–163. <https://doi.org/10.1016/j.ijantimicag.2011.03.020>.

64. Dhanji H, Doumith M, Rooney PJ, O'Leary MC, Loughrey AC, Hope R, Woodford N, Livermore DM. 2011. Molecular epidemiology of fluoroquinolone-resistant ST131 *Escherichia coli* producing CTX-M extended-spectrum beta-lactamases in nursing homes in Belfast, UK. *J Antimicrob Chemother* 66:297–303. <https://doi.org/10.1093/jac/dkq463>.
65. Ho PL, Yeung MK, Lo WU, Tse H, Li Z, Lai EL, Chow KH, To KK, Yam WC. 2012. Predominance of pHK01-like incompatibility group FII plasmids encoding CTX-M-14 among extended-spectrum beta-lactamase-producing *Escherichia coli* in Hong Kong, 1996–2008. *Diagn Microbiol Infect Dis* 73:182–186. <https://doi.org/10.1016/j.diagmicrobio.2012.03.009>.
66. Calhau V, Ribeiro G, Mendonca N, Da Silva GJ. 2013. Prevalent combination of virulence and plasmidic-encoded resistance in ST 131 *Escherichia coli* strains. *Virulence* 4:726–729. <https://doi.org/10.4161/viru.26552>.
67. Weinstein MP. Performance standards for antimicrobial susceptibility testing. Clinical and Laboratory Standards Institute, 2021.
68. Baym M, Kryazhimskiy S, Lieberman TD, Chung H, Desai MM, Kishony R. 2015. Inexpensive multiplexed library preparation for megabase-sized genomes. *PLoS One* 10:e0128036. <https://doi.org/10.1371/journal.pone.0128036>.
69. Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* 30:2114–2120. <https://doi.org/10.1093/bioinformatics/btu170>.
70. Schmieder R, Edwards R. 2011. Fast identification and removal of sequence contamination from genomic and metagenomic datasets. *PLoS One* 6:e17288. <https://doi.org/10.1371/journal.pone.0017288>.
71. Kolmogorov M, Yuan J, Lin Y, Pevzner PA. 2019. Assembly of long, error-prone reads using repeat graphs. *Nat Biotechnol* 37:540–546. <https://doi.org/10.1038/s41587-019-0072-8>.
72. Walker BJ, Abeel T, Shea T, Priest M, Abouelliel A, Sakthikumar S, Cuomo CA, Zeng Q, Wortman J, Young SK, Earl AM. 2014. Pilon: an integrated tool for comprehensive microbial variant detection and genome assembly improvement. *PLoS One* 9:e112963. <https://doi.org/10.1371/journal.pone.0112963>.
73. Seemann T. 2014. Prokka: rapid prokaryotic genome annotation. *Bioinformatics* 30:2068–2069. <https://doi.org/10.1093/bioinformatics/btu153>.
74. Page AJ, Cummins CA, Hunt M, Wong VK, Reuter S, Holden MTG, Fookes M, Falush D, Keane JA, Parkhill J. 2015. Roary: rapid large-scale prokaryote pan genome analysis. *Bioinformatics* 31:3691–3693. <https://doi.org/10.1093/bioinformatics/btv421>.
75. Price MN, Dehal PS, Arkin AP. 2009. FastTree: computing large minimum evolution trees with profiles instead of a distance matrix. *Mol Biol Evol* 26:1641–1650. <https://doi.org/10.1093/molbev/msp077>.
76. Letunic I, Bork P. 2021. Interactive tree of life (iTOL) v5: an online tool for phylogenetic tree display and annotation. *Nucleic Acids Res* 49:W293–W296. <https://doi.org/10.1093/nar/gkab301>.
77. Siguier P, Perochon J, Lestrade L, Mahillon J, Chandler M. 2006. ISfinder: the reference centre for bacterial insertion sequences. *Nucleic Acids Res* 34:D32–36. <https://doi.org/10.1093/nar/gkj014>.
78. Sullivan MJ, Petty NK, Beatson SA. 2011. Easyfig: a genome comparison visualizer. *Bioinformatics* 27:1009–1010. <https://doi.org/10.1093/bioinformatics/btr039>.
79. Carattoli A, Zankari E, García-Fernández A, Voldby Larsen M, Lund O, Villa L, Møller Aarestrup F, Hasman H. 2014. In silico detection and typing of plasmids using PlasmidFinder and plasmid multilocus sequence typing. *Antimicrob Agents Chemother* 58:3895–3903. <https://doi.org/10.1128/AAC.02412-14>.
80. Garcillan-Barcia MP, Redondo-Salvo S, Vielva L, de la Cruz F. 2020. MOBscan: automated Annotation of MOB Relaxases. *Methods Mol Biol* 2075:295–308. [https://doi.org/10.1007/978-1-4939-9877-7\\_21](https://doi.org/10.1007/978-1-4939-9877-7_21).
81. Conesa A, Götz S, García-Gómez JM, Terol J, Talón M, Robles M. 2005. Blast2GO: a universal tool for annotation, visualization and analysis in functional genomics research. *Bioinformatics* 21:3674–3676. <https://doi.org/10.1093/bioinformatics/bti610>.
82. Jain C, Rodriguez RL, Phillipy AM, Konstantinidis KT, Aluru S. 2018. High throughput ANI analysis of 90K prokaryotic genomes reveals clear species boundaries. *Nat Commun* 9:5114. <https://doi.org/10.1038/s41467-018-07641-9>.
83. Jacomy M, Venturini T, Heymann S, Bastian M. 2014. ForceAtlas2, a continuous graph layout algorithm for handy network visualization designed for the Gephi software. *PLoS One* 9:e98679. <https://doi.org/10.1371/journal.pone.0098679>.
84. Subelj L, Bajec M. 2011. Unfolding communities in large complex networks: combining defensive and offensive label propagation for core extraction. *Phys Rev E Stat Nonlin Soft Matter Phys* 83:e036103. <https://doi.org/10.1103/PhysRevE.83.036103>.
85. Lambiotte R, Delvenne J-C, Barahona M. 2014. Random walks, Markov processes and the multiscale modular organization of complex networks. *IEEE Trans Netw Sci Eng* 1:76–90. <https://doi.org/10.1109/TNSE.2015.2391998>.